Production (Stage)
Claritas Pharmaceuticals, Inc.
CLAZF
$0.00
$0.000.00%
OTC PK
| 09/30/2021 | 06/30/2021 | 03/31/2021 | 12/31/2020 | 09/30/2020 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 514.00K | 549.00K | 159.00K | 348.00K | 822.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 514.00K | 549.00K | 159.00K | -1.99M | 822.00K |
| Operating Income | -514.00K | -549.00K | -159.00K | 1.99M | -822.00K |
| Income Before Tax | 181.00K | -1.26M | -2.78M | -598.00K | 58.00K |
| Income Tax Expenses | -- | -- | -476.00K | 56.00K | -- |
| Earnings from Continuing Operations | 181.00K | -1.26M | -2.30M | -654.00K | 58.00K |
| Earnings from Discontinued Operations | -- | -680.00K | -- | -- | -471.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 181.00K | -1.94M | -2.30M | -654.00K | -413.00K |
| EBIT | -514.00K | -549.00K | -159.00K | 1.99M | -822.00K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.01 | -0.06 | -0.08 | -0.02 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | 0.01 | -0.06 | -0.08 | -0.02 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 35.41M | 33.41M | 27.53M | 27.33M | 27.08M |
| Average Diluted Shares Outstanding | 35.41M | 33.41M | 27.53M | 27.33M | 27.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |